Ivermectin, a potential anticancer drug derived from an antiparasitic drug.

Pharmacol Res

Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui Province 233030, China; Department of Microbiology and Parasitology, Bengbu Medical College, Bengbu, Anhui Province 233030, China; School of Fundamental Sciences, Bengbu Medical College, Bengbu, Anhui Province 233030, China. Electronic address:

Published: January 2021

Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114PMC
http://dx.doi.org/10.1016/j.phrs.2020.105207DOI Listing

Publication Analysis

Top Keywords

anticancer drug
12
antiparasitic drug
8
parasitic diseases
8
ivermectin anticancer
8
ivermectin
7
drug
5
ivermectin potential
4
potential anticancer
4
drug derived
4
derived antiparasitic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!